NOCIL starts Saksham Niveshak campaign for KYC updation

1 min read     Updated on 23 May 2026, 01:49 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

NOCIL Limited initiated the 'Saksham Niveshak' campaign from April 1, 2026, to July 9, 2026, to help shareholders update KYC details and claim unpaid dividends. The company urges shareholders to update PAN, bank details, and nominee information to prevent transfer of unclaimed amounts to the IEPF.

powered bylight_fuzz_icon
40973351

*this image is generated using AI for illustrative purposes only.

NOCIL Limited has launched the 'Saksham Niveshak' campaign, a 100-day initiative aimed at facilitating Know Your Customer (KYC) updation and shareholder engagement. The campaign, which runs from April 1, 2026, to July 9, 2026, targets shareholders with unpaid or unclaimed dividends to prevent these amounts from being transferred to the Investor Education and Protection Fund (IEPF).

Campaign Details

The initiative is part of the broader drive by the Investor Education and Protection Authority (IEPFA) for investor education and facilitation. NOCIL Limited has issued a notice urging shareholders to update their details to ensure they receive their entitled dividends and avoid the transfer of shares to the IEPF.

Action Required for Shareholders

Shareholders with unpaid or unclaimed dividends, or those needing to update their KYC details, must take specific actions. The required updates include:

  • PAN details
  • Bank account details and mandates
  • Nominee registration
  • Contact information (email, mobile number, address)

Contact Information

Shareholders can reach out to the company's Registrar and Transfer Agent (RTA), KFin Technologies Limited, or the company directly to resolve queries or update information.

Entity Contact Details
Registrar and Transfer Agent KFin Technologies Limited, Selenium Tower B, Plot 31-32, Financial District, Nanakramguda, Serilingampally, Rangareddy, Telangana, Hyderabad - 500032
RTA Email einward.ris@kfintech.com
Company Email investorcare@nocil.com

The company had previously sent individual communications on May 13, 2026, to shareholders whose dividends remain unpaid or unclaimed. This notice is available on the company's website and the websites of BSE Ltd and National Stock Exchange of India Ltd.

Historical Stock Returns for NOCIL

1 Day5 Days1 Month6 Months1 Year5 Years
-1.40%+0.77%-6.61%-2.45%-9.23%-23.14%

How much total dividend amount and how many shares are at risk of being transferred to the IEPF if NOCIL shareholders fail to complete KYC updates before the July 9, 2026 deadline?

Could the 'Saksham Niveshak' campaign's success influence other listed Indian companies to adopt similar proactive shareholder engagement initiatives ahead of IEPF transfer deadlines?

What long-term impact might a large-scale transfer of unclaimed shares to the IEPF have on NOCIL's shareholder composition and retail investor participation?

NOCIL Q4 FY26 PAT Rs 17 Cr, Volume Grows 7%

4 min read     Updated on 19 May 2026, 01:30 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

NOCIL Limited reported a 5% sequential increase in revenue to Rs 330 crore for Q4 FY26, driven by a 7% volume rise. Profit after tax improved to Rs 17 crore from Rs 9 crore in the preceding quarter. Despite pricing pressures from imports and higher costs, the company anticipates sustained volume growth and has implemented price hikes to mitigate raw material inflation.

powered bylight_fuzz_icon
39732825

*this image is generated using AI for illustrative purposes only.

NOCIL Limited held its earnings call on May 8, 2026, to discuss the operational and financial performance for the quarter and year ended March 31, 2026. The company reported revenue from operations of Rs.330 crores for Q4 FY26, reflecting a sequential growth of 5% and a volume increase of 7%. For the full year FY26, revenue stood at Rs.1,303 crores compared to Rs.1,393 crores in FY25.

Operational Performance

Management attributed the volume growth to improved demand following the implementation of GST 2.0 and strengthened customer partnerships. Domestic volumes witnessed single-digit growth, while international markets also posted steady gains. However, realizations remained under pressure due to the dumping of lower-priced imports. The company stated it is maintaining an optimal balance between price and volume to navigate the evolving global environment.

Financial Highlights

Profit after tax (PAT) for Q4 FY26 stood at Rs.17 crores, compared to Rs.9 crores in the previous quarter. For the full year, PAT was Rs.56 crores against Rs.103 crores in FY25. The decline in profitability was attributed to narrowed spreads due to the Free Trade Agreement (FTA) regime wiping out basic duty protection on certain products, as well as higher utility and maintenance costs during the quarter.

Metric Q4 FY26 Q3 FY26 FY26 FY25
Revenue from Operations (Rs. Cr): 330 316 1,303 1,393
PAT (Rs. Cr): 17 9 56 103

Strategic Updates

The Director General of Trade Remedies (DGTR) recommended positive final findings in March 2026 regarding antidumping petitions for the antioxidant TDQ and Sulphenamides (CBS and NS). These recommendations are subject to central government approvals. On the capex front, the TDQ capex at Dahej has been completed with trial production commenced. The total capex incurred was less than Rs.250 crores. Additionally, the company announced a new capex of Rs.130 crores on March 16, 2026, for a specialty facility expected to be completed by H1 FY28.

Outlook

Looking ahead, NOCIL expects the positive volume momentum to sustain. The company has revised prices upwards for the non-contractual business and from the current quarter for contractual business to address significant raw material price increases. Management remains focused on cost efficiency initiatives, product mix enhancement, and geographical expansion to drive long-term growth.

Historical Stock Returns for NOCIL

1 Day5 Days1 Month6 Months1 Year5 Years
-1.40%+0.77%-6.61%-2.45%-9.23%-23.14%

How quickly could the central government's antidumping duty approvals on Sulphenamides and TDQ translate into meaningful margin recovery, and what is the realistic upside to EBITDA margins if all pending petitions receive favorable rulings?

With tire manufacturers typically requiring 6–8 months for approval cycles, how might NOCIL's new TDQ capacity ramp-up timeline be affected if global tire demand softens due to macroeconomic headwinds or EV adoption shifts?

Given that 65–70% of NOCIL's business is contractual, how will the lag in passing through raw material price increases to contractual customers impact margin trajectory in H1 FY27 compared to the non-contractual segment?

More News on NOCIL

1 Year Returns:-9.23%